News
Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback